BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bokemeyer B. Addressing unmet needs in inflammatory bowel disease. Drug Discovery Today 2015;20:1037-9. [DOI: 10.1016/j.drudis.2015.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial. Inflamm Bowel Dis 2021:izab073. [PMID: 33988236 DOI: 10.1093/ibd/izab073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Schmidt C, Allen S, Kopyt N, Pergola P. Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. J Clin Med 2021;10:4448. [PMID: 34640466 DOI: 10.3390/jcm10194448] [Reference Citation Analysis]
3 Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis 2021;78:846-856.e1. [PMID: 34029682 DOI: 10.1053/j.ajkd.2021.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]